305 related articles for article (PubMed ID: 28359179)
1. Tackling non-muscle invasive bladder cancer in the clinic.
Woldu SL; Şanli Ö; Lotan Y
Expert Rev Anticancer Ther; 2017 May; 17(5):467-480. PubMed ID: 28359179
[TBL] [Abstract][Full Text] [Related]
2. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
3. Current advances in BCG-unresponsive non-muscle invasive bladder cancer.
Tse J; Singla N; Ghandour R; Lotan Y; Margulis V
Expert Opin Investig Drugs; 2019 Sep; 28(9):757-770. PubMed ID: 31412742
[No Abstract] [Full Text] [Related]
4. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
5. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
6. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
8. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.
Peyton CC; Chipollini J; Azizi M; Kamat AM; Gilbert SM; Spiess PE
World J Urol; 2019 Oct; 37(10):2017-2029. PubMed ID: 30535583
[TBL] [Abstract][Full Text] [Related]
9. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
[TBL] [Abstract][Full Text] [Related]
10. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.
Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
Eur Urol; 2011 Jun; 59(6):997-1008. PubMed ID: 21458150
[TBL] [Abstract][Full Text] [Related]
12. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
13. Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer.
Moussa M; Papatsoris AG; Dellis A; Abou Chakra M; Saad W
Expert Rev Anticancer Ther; 2020 Nov; 20(11):965-983. PubMed ID: 32915676
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
15. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
16. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.
Abufaraj M; Mostafid H; Shariat SF; Babjuk M
Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122
[TBL] [Abstract][Full Text] [Related]
17. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Crijnen J; De Reijke TM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950
[TBL] [Abstract][Full Text] [Related]
18. Intravesical therapy for bladder cancer.
Patel SG; Cohen A; Weiner AB; Steinberg GD
Expert Opin Pharmacother; 2015 Apr; 16(6):889-901. PubMed ID: 25773220
[TBL] [Abstract][Full Text] [Related]
19. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy.
Marchioni M; Nazzani S; Preisser F; Bandini M; Karakiewicz PI
Expert Rev Anticancer Ther; 2018 Apr; 18(4):377-387. PubMed ID: 29429376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
